Member Info for Tim45

Dr Faucci's presentations are so frustrating. I know that we are all on tenterhooks and we have a very special interest in SNG001 being successful but how can he talk about 'preparedness' for future pandemics and NOT mention the role of inhaled mutation-agnostic interferons?

Who knows? An update on ACTIV-2 dosing from Dr Faucci? Or possibly vaccines, vaccines, more vaccines, some vaccine charts and finally three questions on vaccines.

Watch the live update here: https://www.c-span.org/video/?509888-1/white-house-covid-19-response-team-briefing

I missed out that virtually all of the drugs he mentions are intravenous, so they are not suitable for unassisted home use. This has to be one of SNG001's greatest attributes.

Dr Fauci just now summarised the various mabs being trialled with results. He mentioned that single drugs are 'knocked out by variants' which is why 'co cktails' of drugs are looking more promising.

No mention of inhaled interferons though, so frustrating. I am putting this up simply for completeness - we can't ignore the fact that other treatments (and preventative drugs) are delivering impressive data on keeping people out of hospital.

Would anyone be able to comment on his presentation? Others on this BB have highlighted that mabs are expensive to manufacture and still require an injection.

The video (from 17.18) is at: https://www.c-span.org/video/?509841-1/white-house-covid-19-response-team-briefing

Matterhorn - I can't see PharmaTex in the ACTIV trial site list at:
https://clinicaltrials.gov/ct2/show/NCT04518410

Click on 'Locations - Show Show 95 study locations' for full list. Where was PharmaTex listed?

Thanks Jaffjoon ... just vaccines, vaccines and then finally, something on vaccines.

It's Wednesday and it's raining so why not watch the update? One day, one day, the subject will be ACTIV-2 treatments!

https://www.c-span.org/video/?509764-1/white-house-covid-19-response-team-briefing

exygen? I've discovered a new gas ...

Chippy - but if SH thought SNG001 'wouldn’t be effective' after admission to hospital, why bother to do a P3 as well as the Home Trial?

P2 was for hospitalised patients and it returned good results. Surely the issue is not that SNG001 might not help patients in hospital and on exygen but that, caught earlier (at home) it would be even MORE effective? (sorry, I'm not bold-shouting but you can't use italics on this BB)

Why would SNG001 not also be included on ACTIV-3 for in-patient treatment? There will now be places to fill on ACTIV-3.
After all, Brii-196 & Brii-198 are/were put on both ACTIV-2 AND ACTIV-3?

Or do the NIH feel this would be unnecessary, since Synairgen is already running its own P3 for US in-patients?

Volatility - I have so many green boxes that I never see their posts, whoever they are! I broke my British '13 consecutive green boxes' record today ...

Just re-read my posts about ACTIV-3. I put this up purely as an update on this dynamic situation.
I take no pleasure at all from a potential treatment failing - we need different treatments to succeed for each stage of the infection and SNG001 is only one of them.

The ACTIV-3 trial is now showing three out of the four listed candidates as 'ended' - Eli Lilly's LY-CoV-555 due to 'lack of clinical benefit '.

https://www.nih.gov/activ/nih-funded-activ/activ-associated-clinical-trials

NIH reports that BRII-196 and BRII-198 (Monoclonal Antibody ****tails) from Brii Biosciences has 'closed enrollment', in not meeting criteria for inclusion in ACTIV-3 for in-patients.

However, BRII-196 and BRII-198 are both listed together with SNG001 in the activ-2 trials. Will they also be removed from the ACTIV-2 list?

The monoclonal antibody therapy VIR-7831 from GSK-Vir has also not met criterai for ACTIV-3.

NIH article at: https://www.nih.gov/news-events/news-releases/nih-sponsored-activ-3-clinical-trial-closes-enrollment-into-two-sub-studies

Just goes to show how energetically (and ruthlessly) these trials are being studied. I assume other candidate treatments will replace them.

Video not working on Firefox but playing OK on Chrome.

Always worth keeping an eye on. One day, Dr Faucci will speak about ACTIV-2 trial progress as well as vaccines!

Link at: https://www.youtube.com/watch?v=_pST009rSMk

Why keep reacting to him/her? It just keeps it going and fills my screen with green boxes!

Interesting that the question on inhaled budesonide disappeared from the question list. All the others remained.

Totally agree Oak - he presented a proper 'story' of the drug's action and evolution. By far the most impressive member but a pity the University was still connected via dial-up! The AZ R&D boss seemed distracted and rather disinterested to me.

The presenter just said that the proceedings would be on the ERS site, but whether that will be a recorded video or just a transcript wasn't clear. I'll keep looking.